XML 71 R47.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Reconciliation of revenue from segments to consolidated | The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:
|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Total revenue |  | $ | 2,645.5 |  |  | $ | 2,464.9 |  |  | $ | 5,076.5 |  |  | $ | 4,755.4 |
Less cost and expense: |  |  |  |  |  |  |  |
Cost of sales, excluding amortization and impairment of acquired intangible assets: |  |  |  |  |  |  |  |
Product cost of sales |  | 415.0 |  |  | 358.4 |  |  | 877.2 |  |  | 736.1 |
Royalty cost of sales |  | 190.0 |  |  | 187.6 |  |  | 357.1 |  |  | 352.1 |
Research and development: |  |  |  |  |  |  |  |
Research and discovery |  | 46.6 |  |  | 45.7 |  |  | 90.9 |  |  | 93.3 |
Early stage programs |  | 51.9 |  |  | 66.6 |  |  | 124.3 |  |  | 150.7 |
Late stage programs |  | 44.6 |  |  | 46.7 |  |  | 94.0 |  |  | 79.3 |
Marketed products |  | 87.7 |  |  | 170.0 |  |  | 177.2 |  |  | 288.1 |
Other research and development costs(1) |  | 168.2 |  |  | 176.4 |  |  | 346.7 |  |  | 339.4 |
Acquired in-process research and development, upfront and milestone expense |  | 46.6 |  |  | 8.5 |  |  | 247.3 |  |  | 16.0 |
Selling, general and administrative |  | 583.8 |  |  | 553.8 |  |  | 1,156.3 |  |  | 1,135.3 |
Other segment expense(2) |  | 376.3 |  |  | 267.6 |  |  | 730.2 |  |  | 588.1 |
Net Income attributable to Biogen Inc. |  | $ | 634.8 |  |  | $ | 583.6 |  |  | $ | 875.3 |  |  | $ | 977.0 |
(1) Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage. (2) Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; gain on sale of priority review voucher, net; other (income) expense, net; and income tax (benefit) expense

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration